← Back to headlines
Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry
Piper Sandler analysts foresee a path to growth for Bristol-Myers Squibb Company (BMY) following the expiry of its Eliquis patent, suggesting new opportunities for the pharmaceutical firm.
12 Mar, 06:36 — 12 Mar, 06:36
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Philippine Official Calls for Probe into Oil Industry Cartel
just now
Philippine President Marcos orders P8-billion aid distribution
just now
Philippines No Longer Southeast Asia's Worst for Fuel Price Hikes, Economic Pain Persists
just now